This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Find eligible patients in EMIS for Shingles Vaccination through the National Immunisation Programme

This series of 'how to' videos will demonstrate:

  • How to perform EMIS searches and how to mail merge.
  • How to edit searches, text invite patients and set up alerts.
  • How to invite patients who have previously declined the shingles vaccination

This promotional and educational activity has been organised and fully funded by MSD to support the implementation of the shingles national immunisation programme. MSD manufactures the live attenuated shingles vaccine ZOSTAVAX® (shingles (herpes zoster) vaccine live) currently offered in the programme

ZOSTAVAX® is indicated for the prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN). ZOSTAVAX is indicated for immunisation of individuals 50 years of age or older.”

Usual safety considerations for live vaccines apply. Always refer to the Summary of Product Characteristics on the eMC website before prescribing, particularly with regards to contraindications and precautions. MSD does not recommend the use of any of its products in any manner other than stated in the current Summary of Product Characteristics available on the eMC website.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-CIN-00015 | Date of Preparation: January 2019

EMIS

Updated on 23/01/2019

VACCINES
 

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-CIN-00015 | Date of Preparation: January 2019